Copyright
©The Author(s) 2016.
World J Gastroenterol. Aug 28, 2016; 22(32): 7215-7225
Published online Aug 28, 2016. doi: 10.3748/wjg.v22.i32.7215
Published online Aug 28, 2016. doi: 10.3748/wjg.v22.i32.7215
Study | Selection | Treatment | Response | Resection |
Van Cutsem et al[88] 2009 | Unselected | Bevacizumab + chemotherapy (FOLFOX/FOLFIRI) | NA | 11.8% |
6% (R0) | ||||
Okines et al[89] 2009 | Unselected | Bevacizumab + Oxaliplatin-based chemotherapy | 38% | 6.3% |
Wong et al[90] 2011 | Unselected | Bevacizumab + XELOX | 68% | 48.0% |
Loupakis et al[91] 2013 | Unselected | Bevacizumab + FOLFOXIRI | 64% | 15.0% |
Martin et al[92] 2014 | Unselected | Bevacizumab + FOLFOX + DEBIRI | 78% | 35.0% |
Bokemeyer et al[94] 2009 | KRAS WT | Cetuximab + FOLFOX | 57% | 7.3% |
4.7 (R0) | ||||
Van Cutsem et al[95] 2011 | KRAS WT | Cetuximab + FOLFIRI | 57% | 16.0% |
7% (R0) | ||||
Folprecht et al[22] 2010 | KRAS WT | Cetuximab + chemotherapy (FOLFOX/FOLFIRI) | 68% | 43.0% |
34% (R0) | ||||
Garufi et al[96] 2010 | KRAS WT | Cetuximab + FOLFOXIRI | 79% | 60.0% |
Ye et al[97] 2013 | KRAS WT | Cetuximab + FOLFOXIRI | 57% | 25% (R0) |
Köhne et al[100] 2012 | KRAS WT | Panitumumab + FOLFIRI | 56% | 15.0% |
Douillard et al[101] 2010 | KRAS WT | Panitumumab + FOLFOX | 57% | 27.0% |
5.2% (R0) | ||||
NRAS WT | Panitumumab + FOLFOX | 31.0% |
- Citation: De Greef K, Rolfo C, Russo A, Chapelle T, Bronte G, Passiglia F, Coelho A, Papadimitriou K, Peeters M. Multisciplinary management of patients with liver metastasis from colorectal cancer. World J Gastroenterol 2016; 22(32): 7215-7225
- URL: https://www.wjgnet.com/1007-9327/full/v22/i32/7215.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i32.7215